

NYRx Drug Class Coverage Overview: Glucagon-Like Peptide-1 (GLP-1) Agonists

NYRx Preferred Drug List

Drugs in the Glucagon-Like Peptide-1 (GLP-1) Agonists drug class are included on the [NYRx Preferred Drug List \(PDL\)](#) and are subject to prior authorization (PA) requirements of the [NYRx Drug Utilization Review \(DUR\) Program](#):

Preferred Drugs	Non-Preferred Drugs	Prior Authorization/Coverage Parameters
VI. Endocrine and Metabolic Agents		
Glucagon-like Peptide-1 (GLP-1) Agonists ^{CC, ST}		
Byetta® Ozempic® Trulicity® Victoza®	Adlyxin® Bydureon® BCise™ Mounjaro® Rybelsus® Soliqua® Xultophy®	CLINICAL CRITERIA (CC) <ul style="list-style-type: none"> Confirm diagnosis of FDA-approved, compendia-supported, and Medicaid-covered indication STEP THERAPY (ST) <ul style="list-style-type: none"> Trial with metformin with or without insulin prior to initiating GLP-1 agonist therapy unless there is a contraindication, or the drug is being used for an FDA-approved Medicaid covered indication other than, or in addition to, Type 2 Diabetes.

NYRx, the Medicaid pharmacy program, covers medically necessary FDA-approved drugs when used for Medicaid-covered indications. Certain drugs, drug classes, or drug indications including weight loss are excluded from coverage pursuant to federal or state law and regulation. Exclusions include agents when used for the treatment of anorexia, weight loss, or weight gain [18 NYCRR§505.3(g)(3)]. For example, but not limited to:

- GLP-1 Agonists for weight loss
- SGLT-2 Inhibitors for weight loss

Weight loss is not and never has been a Medicaid-covered indication. GLP-1 Agonists, including but not limited to Ozempic, Wegovy, and Mounjaro are excluded from coverage for weight loss indications. Editing has been enhanced to ensure that members with Medicaid-covered indications have access to these medications. For more information, please refer to the [NYRx Excluded Diagnoses](#).

Prior Authorization Requirements

- Preferred drugs will not require PA if the required coverage parameters are found in the member’s Medicaid claim history at the time of pharmacy claim submission. Providers should include all applicable diagnosis codes in a member’s electronic medical record (EMR) and submit their claims in a timely manner to decrease the need to manually obtain PA.

- Non-preferred drugs will require PA.
- All drugs in the Glucagon-like Peptide-1 (GLP-1) Agonists class are subject to Clinical Criteria (CC) and Step Therapy (ST) requirements:
 - Clinical criteria must confirm the diagnosis of FDA-approved, compendia-supported, and Medicaid-covered indication.
 - Step therapy requires a trial with metformin with or without insulin prior to initiating GLP-1 agonist therapy unless there is a contraindication, or the drug is being used for an FDA-approved Medicaid-covered indication other than, or in addition to, Type 2 Diabetes.

What Pharmacy Providers Need to Do

Pharmacy providers should become familiar with the NYRx Glucagon-like Peptide-1 (GLP-1) Agonists coverage criteria and the [PDL](#) and incorporate this information when discussing the need for PA with prescribers.

What Prescribers Need to Do

Prescribers should become familiar with the Glucagon-like Peptide-1 (GLP-1) Agonists coverage criteria and the [PDL](#) and incorporate this information when prescribing for Medicaid members.

Resources

- [NYRx Education & Outreach Website](#)
- [NYRx Excluded Diagnoses](#)
- [NYRx Preferred Drug List](#)
- [NYRx Prior Authorization Form](#)
- [NYRx Prior Authorization Submission Guide](#)
- [NYRx Step Therapy](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.